Loading clinical trials...
Loading clinical trials...
A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE
The aim of this study was to determine whether long-term (≥ 6 months at the target dose) blockade of ETA receptors using sitaxsentan showed functional benefit in subjects with chronic Heart Failure and an Left Ventricular Ejection Fraction ≥50%.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mobile Heart Specialists, PC
Mobile, Alabama, United States
Preventative and Research Cardiloogy Providence Hospital
Mobile, Alabama, United States
Central Arkansas Veterans HCS
Little Rock, Alaska, United States
Arizona Pulmonary Specialists, LTD
Phoenix, Arizona, United States
Parkview Research Center
Tucson, Arizona, United States
Southwest Heart
Tucson, Arizona, United States
University of Arkansas for Medical Services/Cardiology Department
Little Rock, Arkansas, United States
University of Southern California Medical Center
Los Angeles, California, United States
Orange County Heart Institute and Research Center
Orange, California, United States
Start Date
March 27, 2006
Primary Completion Date
May 1, 2008
Completion Date
May 1, 2008
Last Updated
January 4, 2023
200
ACTUAL participants
Sitexsentin sodium
DRUG
Placebo
DRUG
Lead Sponsor
Pfizer
NCT05064709
NCT03338374
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04721314